Epidermal Growth Factor Receptor-Targeted Therapy for Pancreatic Cancer

REFERENCES

• Hubbard S. R. EGF receptor activation: push comes to shove. Cell 2006; 125: 1029–1031
   PubMed Web of Science ®Google Scholar
• Yarden Y., Sliwkowski M. X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2001; 2: 127–137
   PubMed Web of Science ®Google Scholar
• Xiong H. Q., Abbruzzese J. L. Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin. Oncol. 2002; 29: 31–37, (5 Suppl. 14)
   PubMed Web of Science ®Google Scholar
• L'Allemain G., et al. Signal transduction in hamster fibroblasts overexpressing the human EGF receptor. Growth Factors 1989; 1(4)311–321
   PubMedGoogle Scholar
• Velu T. J., et al. Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene. Science 1987; 238(4832)1408–1410
   PubMed Web of Science ®Google Scholar
• Quon H., Liu F. F., Cummings B. J. Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck 2001; 23(2)147–159
   PubMed Web of Science ®Google Scholar
• Skirnisdottir I., et al. Clinical and biological characteristics of clear cell carcinomas of the ovary in FIGO stages I-II. Int. J. Oncol. 2005; 26(1)177–183
   PubMed Web of Science ®Google Scholar
• Skirnisdottir I., Seidal T., Sorbe B. A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging. Int. J. Gynecol. Cancer 2004; 14(2)259–270
   PubMed Web of Science ®Google Scholar
• Pawlowski V., et al. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin. Cancer Res. 2000; 6(11)4217–4225
   PubMed Web of Science ®Google Scholar
• Mayer A., et al. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993; 71(8)2454–2460
   PubMed Web of Science ®Google Scholar
• Yamanaka Y., et al. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 1993; 13(3)565–569
   PubMed Web of Science ®Google Scholar
• Friess H., et al. Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression. Clin. Cancer Res. 1995; 1(11)1413–1420
   PubMed Web of Science ®Google Scholar
• Dawson J. P., et al. Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. Mol. Cell Biol. 2005; 25(17)7734–7742
   PubMed Web of Science ®Google Scholar
• Klein P., et al. A structure-based model for ligand binding and dimerization of EGF receptors. Proc. Natl. Acad. Sci. U.S.A. 2004; 101(4)929–934
   PubMed Web of Science ®Google Scholar
• Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 2002; 110(6)669–672
   PubMed Web of Science ®Google Scholar
• Hubbard S. R. Autoinhibitory mechanisms in receptor tyrosine kinases. Front Biosci. 2002; 7: d330–d340
   PubMed Web of Science ®Google Scholar
• Hubbard S. R. Juxtamembrane autoinhibition in receptor tyrosine kinases. Nat. Rev. Mol. Cell Biol. 2004; 5(6)464–471
   PubMed Web of Science ®Google Scholar
• Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103(2)211–225
   PubMed Web of Science ®Google Scholar
• Burgess A. W., et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol. Cell 2003; 12(12)3–541
   PubMedGoogle Scholar
• Tibes R., Trent J., Kurzrock R. Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. Annu. Rev. Pharmacol. Toxicol. 2005; 45: 357–384
   PubMed Web of Science ®Google Scholar
• Huse M., Kuriyan J. The conformational plasticity of protein kinases. Cell 2002; 109(3)275–282
   PubMed Web of Science ®Google Scholar
• Hubbard S. R., Till J. H. Protein tyrosine kinase structure and function. Annu. Rev. Biochem. 2000; 69: 373–398
   PubMed Web of Science ®Google Scholar
• Ullrich A., Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990; 61(2)203–212
   PubMed Web of Science ®Google Scholar
• Heldin C. H. Dimerization of cell surface receptors in signal transduction. Cell 1995; 80(2)213–223
   PubMed Web of Science ®Google Scholar
• Heldin C. H., Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev. 1999; 79(4)1283–1316
   PubMed Web of Science ®Google Scholar
• Burke C. L., Stern D. F. Activation of Neu (ErbB-2) mediated by disulfide bond-induced dimerization reveals a receptor tyrosine kinase dimer interface. Mol. Cell Biol. 1998; 18(9)5371–5379
   PubMed Web of Science ®Google Scholar
• Gotoh N., et al. A highly conserved tyrosine residue at codon 845 within the kinase domain is not required for the transforming activity of human epidermal growth factor receptor. Biochem. Biophys. Res. Commun. 1992; 186(186)2–768
   Google Scholar
• Moriki T., Maruyama H., Maruyama I. N. Activation of preformed EGF receptor dimers by ligand-induced rotation of the transmembrane domain. J. Mol. Biol. 2001; 311(5)1011–1026
   PubMed Web of Science ®Google Scholar
• Stamos J., Sliwkowski M. X., Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 2002; 277(48)46265–46272
   PubMed Web of Science ®Google Scholar
• Zhang X., et al. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006; 125(125)6–1137
   Google Scholar
• Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur. J. Cancer 2001; 37: S3–S8, (Suppl 4)
   PubMed Web of Science ®Google Scholar
• Minna J. D., et al. Cancer. A bull's eye for targeted lung cancer therapy. Science 2004; 304(304)5676–1458
   Google Scholar
• Dowell J. E., Minna J. D. EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer. Nat. Clin. Pract. Oncol. 2006; 3(4)170–171
   PubMedGoogle Scholar
• Lynch T. J., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004; 350(350)21–2129
   PubMedGoogle Scholar
• Xiong H. Q., et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J. Clin. Oncol. 2004; 22(22)13–2610
   Google Scholar
• Bloomston M., et al. Epidermal Growth Factor Receptor Expression in Pancreatic Carcinoma Using Tissue Microarray Technique. Dig. Surg. 2006; 23(1–2)74–79
   PubMed Web of Science ®Google Scholar
• Funatomi H., et al. Amphiregulin antisense oligonucleotide inhibits the growth of T3M4 human pancreatic cancer cells and sensitizes the cells to EGF receptor-targeted therapy. Int. J. Cancer 1997; 72(3)512–517
   PubMed Web of Science ®Google Scholar
• Perrotte P., et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res. 1999; 5(5)2–257
   Google Scholar
• Carpenter G. Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem 1987; 56: 881–914
   PubMed Web of Science ®Google Scholar
• Ogiso H., et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002; 110(110)6–775
   Google Scholar
• Prenzel N., et al. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr. Relat. Cancer 2001; 8(8)1–11
   Google Scholar
• Masuda M., et al. The roles of JNK1 and Stat3 in the response of head and neck cancer cell lines to combined treatment with all-trans-retinoic acid and 5-fluorouracil. Jpn. J. Cancer Res. 2002; 93(93)3–329
   Google Scholar
• Grandis J. R., et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. J. Clin. Invest. 1998; 102(102)7–1385
   Google Scholar
• Niu G., et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002; 21(21)13–2000
   Google Scholar
• Bancroft C. C., et al. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int. J. Cancer 2002; 99(99)4–538
   Google Scholar
• Le X., et al. Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinoma. J. Interferon. Cytokine. Res. 2000; 20(20)11–935
   Google Scholar
• Shi Q., et al. Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin. Cancer Res. 1999; 5(5)11–3711
   Google Scholar
• Kim G. E., et al. Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival. Clin. Cancer Res. 2004; 10(10)4–1366
   PubMedGoogle Scholar
• Shao J., et al. Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin. Cancer Res. 2003; 63(63)17–5218
   Google Scholar
• Pai R., et al. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat. Med. 2002; 8(8)3–289
   PubMedGoogle Scholar
• Sales K. J., Maudsley S., Jabbour H. N. Elevated prostaglandin EP2 receptor in endometrial adenocarcinoma cells promotes vascular endothelial growth factor expression via cyclic 3′,5′-adenosine monophosphate-mediated transactivation of the epidermal growth factor receptor and extracellular signal-regulated kinase 1/2 signaling pathways. Mol. Endocrinol. 2004; 18(6)1533–1545
   PubMed Web of Science ®Google Scholar
• Buchanan F. G., et al. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J. Biol. Chem. 2003; 278(278)37–35451
   PubMedGoogle Scholar
• Shao J., Evers B. M., Sheng H. Prostaglandin E2 synergistically enhances receptor tyrosine kinase-dependent signaling system in colon cancer cells. J. Biol. Chem. 2004; 279(14)14287–14293
   PubMed Web of Science ®Google Scholar
• Turini M. E., DuBois R. N. Cyclooxygenase-2: a therapeutic target. Annu. Rev. Med. 2002; 53: 35–57
   PubMed Web of Science ®Google Scholar
• Masferrer J. L., Koki A., Seibert K. COX-2 inhibitors. A new class of antiangiogenic agents. Ann. N.Y. Acad. Sci. 1999; 889: 84–86
   PubMed Web of Science ®Google Scholar
• Wang D., DuBois R. N. Cyclooxygenase 2-derived prostaglandin E2 regulates the angiogenic switch. Proc. Natl. Acad. Sci. U.S.A. 2004; 101(2)415–416
   PubMed Web of Science ®Google Scholar
• Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis. Rev. 2000; 19(1–2)19–27
   PubMed Web of Science ®Google Scholar
• Wedge S. R., et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002; 62(62)16–4645
   Google Scholar
• Ciardiello F., et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin. Cancer Res. 2003; 9(9)4–1546
   Google Scholar
• Tuccillo C., et al. Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor. Clin. Cancer Res. 2005; 11(11)3–1268
   Google Scholar
• Landis S. H., et al. Cancer statistics, 1999. CA. Cancer J. Clin. 1999; 49(1)8–31; 1
   PubMed Web of Science ®Google Scholar
• Hawes R. H., et al. A multispecialty approach to the diagnosis and management of pancreatic cancer. Am. J. Gastroenterol. 2000; 95(95)1–17
   Google Scholar
• Burris H. A., 3rd, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997; 15(6)2403–2413
   PubMed Web of Science ®Google Scholar
• Berlin J. D., et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J. Clin. Oncol. 2002; 20(15)3270–3275
   PubMed Web of Science ®Google Scholar
• Oettle H., et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann. Oncol. 2005; 16(16)10–1639
   Google Scholar
• Rocha Lima C. M., et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J. Clin. Oncol. 2004; 22(18)3776–3783
   PubMed Web of Science ®Google Scholar
• Reni M., et al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet. Oncol. 2005; 6(6)6–369
   Google Scholar
• Louvet C., et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J. Clin. Oncol. 2005; 23(23)15–3509
   Google Scholar
• Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr. Relat. Cancer 2001; 8(1)3–9
   PubMed Web of Science ®Google Scholar
• Bruns C. J., et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 2000; 60(11)2926–2935
   PubMed Web of Science ®Google Scholar
• Aboud-Pirak E., et al. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J. Natl. Cancer Inst. 1988; 80(80)20–1605
   Google Scholar
• Baselga J., Averbuch S. D. ZD1839 (‘Iressa’) as an anticancer agent. Drugs 2000; 60: 33–40, Suppl 1 discussion 41–2
   PubMed Web of Science ®Google Scholar
• Erlichman C., et al. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res. 2001; 61(2)739–748
   PubMed Web of Science ®Google Scholar
• Brown D., Wang R., Russell P. Antiepidermal growth factor receptor antibodies augment cytotoxicity of chemotherapeutic agents on squamous cell carcinoma cell lines. Otolaryngol. Head Neck Surg. 2000; 122(1)75–83
   PubMed Web of Science ®Google Scholar
• Pollack V. A., et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J. Pharmacol. Exp. Ther. 1999; 291(291)2–739
   Google Scholar
• Rao G. S., Murray S., Ethier S. P. Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. Int. J. Radiat. Oncol. Biol. Phys. 2000; 48(5)1519–1528
   PubMed Web of Science ®Google Scholar
• Williams K. J., et al. ZD1839 (‘Iressa’), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br. J. Cancer 2002; 86(7)1157–1161
   PubMed Web of Science ®Google Scholar
• Krempien R., et al. Randomized phase II–study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer–PARC: study protocol [ISRCTN56652283]. BMC Cancer 2005; 5: 131
   PubMedGoogle Scholar
• Inoue K., et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin. Cancer Res. 2000; 6(6)12–4874
   Google Scholar
• Herbst R. S., Shin D. M. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002; 94(5)1593–1611
   PubMed Web of Science ®Google Scholar
• Morelli M. P., et al. Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Ann. Oncol. 2005; 16: iv61–iv68, (Suppl 4)
   PubMedGoogle Scholar
• Lu Y., et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J. Natl. Cancer Inst. 2001; 93(93)24–1852
   Google Scholar
• Viloria-Petit A., et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 2001; 61(61)13–5090
   Google Scholar
• Chakravarti A., Loeffler J. S., Dyson N. J. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res. 2002; 62(1)200–207
   PubMed Web of Science ®Google Scholar
• Bianco R., et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003; 22(22)18–2812
   Google Scholar
• She Q. B., et al. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clin. Cancer Res. 2003; 9(9)12–4340
   Google Scholar
• O'Reilly M. S. Targeting multiple biological pathways as a strategy to improve the treatment of cancer. Clin. Cancer Res. 2002; 8(11)3309–3310
   PubMed Web of Science ®Google Scholar
• Jemal A., et al. Cancer statistics, 2005. CA Cancer J. Clin. 2005; 55(55)1–10
   PubMedGoogle Scholar
• Mendelsohn J., Fan Z. Epidermal growth factor receptor family and chemosensitization. J. Natl. Cancer Inst. 1997; 89(5)341–343
   PubMed Web of Science ®Google Scholar
• Melisi D., et al. Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments. Endocr. Relat. Cancer 2004; 11(11)1–51
   PubMedGoogle Scholar
• Crane C. H., et al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?. Int. J. Radiat. Oncol. Biol. Phys. 2002; 52(52)5–1293
   Google Scholar
• Erickson B. A., Nag S. Biliary tree malignancies. J. Surg. Oncol. 1998; 67(3)203–210
   PubMed Web of Science ®Google Scholar
• Pino S. M., et al. Novel therapies for pancreatic adenocarcinoma. Curr. Gastroenterol Rep. 2004; 6(6)2–119
   Google Scholar
• Dhar A., et al. Epidermal growth factor receptor: is a novel therapeutic target for pancreatic cancer?. Front Biosci. 2005; 10: 1763–1767
   PubMed Web of Science ®Google Scholar
• Ciardiello F., et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 2000; 6(6)5–2053
   Google Scholar
• Ciardiello F., et al. ZD1839 (Iressa): preclinical studies and pharmacology. Tumori 2002; 88: S155–S157, (1 Suppl 1)
   PubMed Web of Science ®Google Scholar
• Hidalgo M., et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. 2001; 19(13)3267–3279
   PubMed Web of Science ®Google Scholar
• Torrance C. J., et al. Combinatorial chemoprevention of intestinal neoplasia. Nat. Med. 2000; 6(6)9–1024
   Google Scholar
• Raz D. J., et al. Current concepts in bronchioloalveolar carcinoma biology. Clin. Cancer Res. 2006; 12(12)12–3698
   Google Scholar
• Bunn P. A., Jr., et al. Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy. Clin. Cancer Res. 2006; 12(12)3652–3656
   PubMed Web of Science ®Google Scholar
• Inoue A., et al. Prospective Phase II Study of Gefitinib for Chemotherapy-Naive Patients With Advanced Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene Mutations. J. Clin. Oncol. 2006
   Google Scholar
• Jackman D. M., et al. Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non-Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib. Clin. Cancer Res. 2006; 12(13)3908–3914
   PubMed Web of Science ®Google Scholar
• Janne P. A. Gefitinib for Epidermal Growth Factor Receptor Mutant Lung Cancers: Searching for a Weapon of Mass Destruction. J. Clin. Oncol. 2006
   Google Scholar
• Jiang J., et al. Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res. 2005; 65(65)19–8968
   Google Scholar
• Mukohara T., et al. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J. Natl. Cancer Inst. 2005; 97(97)16–1185
   Google Scholar
• Baselga J., et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2005; 23(24)5568–5577
   PubMed Web of Science ®Google Scholar
• Bogart J. A., Govindan R. A randomized phase II study of radiation therapy, pemetrexed, and carboplatin with or without cetuximab in stage III non-small-cell lung cancer. Clin. Lung Cancer 2006; 7(4)285–287
   PubMed Web of Science ®Google Scholar
• Bourhis J., et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2006; 24(24)18–2866
   Google Scholar
• Chan A. T., et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J. Clin. Oncol. 2005; 23(23)15–3568
   Google Scholar
• Combs S. E., et al. Treatment of Primary Glioblastoma Multiforme with Cetuximab, Radiotherapy and Temozolomide (GERT) - Phase I/II Trial: Study Protocol. BMC Cancer. 2006; 6(1)133
   PubMedGoogle Scholar
• Herbst R. S., et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23(24)5578–5587
   PubMed Web of Science ®Google Scholar
• Pfister D. G., et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J. Clin. Oncol. 2006; 24(24)7–1072
   Google Scholar
• Saltz L. B., et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 2004; 22(7)1201–1208
   PubMed Web of Science ®Google Scholar
• Thienelt C. D., et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J. Clin. Oncol. 2005; 23(34)8786–8793
   PubMed Web of Science ®Google Scholar
• Vincenzi B., et al. Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. Br. J. Cancer 2006; 94(94)6–792
   Google Scholar
• SWOG S0502: Phase III Randomized Study of Gemcitabine With Versus Without Cetuximab as First-Line Therapy in Patients With Locally Advanced Unrestable or Metastatic Adenocarcinoma of the Pancreas. Clin. Adv. Hematol. Oncol. 2004; 2(4)201–252
   Google Scholar
• Alberts S. R., Sinicrope F. A., Grothey A. N0147: a randomized phase III trial of oxaliplatin plus 5-fluorouracil/leucovorin with or without cetuximab after curative resection of stage III colon cancer. Clin. Colorectal Cancer. 2005; 5(3)211–213
   PubMedGoogle Scholar
• Burtness B., et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 2005; 23(34)8646–8654
   PubMed Web of Science ®Google Scholar
• Goldstein N. I., et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1995; 1(1)11–1311
   PubMedGoogle Scholar
• Gill G. N., et al. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J. Biol. Chem. 1984; 259(259)12–7755
   PubMedGoogle Scholar
• Sato J. D., et al. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol. Biol. Med. 1983; 1(1)5–511
   Google Scholar
• Modjtahedi H., et al. Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br. J. Cancer 1996; 73(2)228–235
   PubMed Web of Science ®Google Scholar
• Modjtahedi H., et al. Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy. Int. J. Cancer 2003; 105(105)2–273
   Google Scholar
• Foon K. A., et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int. J. Radiat. Oncol. Biol. Phys. 2004; 58(58)3–984
   PubMedGoogle Scholar
• Lynch D. H., Yang X. D. Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin. Oncol. 2002; 29: 47–50, (1 Suppl 4)
   PubMed Web of Science ®Google Scholar
• Ranson M. Technology evaluation: ABX-EGF, Abgenix/Amgen. Curr. Opin. Mol. Ther. 2003; 5(5)541–546
   PubMed Web of Science ®Google Scholar
• Rowinsky E. K., et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J. Clin. Oncol. 2004; 22(22)15–3003
   PubMedGoogle Scholar
• Tyagi P. Recent results and ongoing trials with panitumumab (ABX-EGF), a fully human anti-epidermal growth factor receptor antibody, in metastatic colorectal cancer. Clin. Colorectal. Cancer 2005; 5(1)21–23
   PubMedGoogle Scholar
• Yang X. D., et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit. Rev. Oncol. Hematol. 2001; 38(38)1–17
   PubMedGoogle Scholar
• Bangard C., et al. Magnetic resonance imaging in an orthotopic rat model: blockade of epidermal growth factor receptor with EMD72000 inhibits human pancreatic carcinoma growth. Int. J. Cancer 2005; 114(114)1–131
   PubMedGoogle Scholar
• Mamot C., et al. EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells. J. Drug Target 2006; 14(14)4–215
   Google Scholar
• Vanhoefer U., et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J. Clin. Oncol. 2004; 22(1)175–184
   PubMed Web of Science ®Google Scholar
• Yang X. D., et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 1999; 59(59)6–1236
   Google Scholar
• Bruns C. J., et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin. Cancer Res. 2000; 6(6)5–1936
   Google Scholar
• Smith K., et al. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer. Cancer Res. 2005; 65(65)12–5221
   Google Scholar
• Zhang M., et al. Silencing the epidermal growth factor receptor gene with RNAi may be developed as a potential therapy for non small cell lung cancer. Genet. Vaccines Ther. 2005; 3: 5
   PubMedGoogle Scholar
• Ciardiello F., et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin. Cancer Res. 2000; 6(6)9–3739
   Google Scholar
• Baselga J., et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. 2000; 18(4)904–914
   PubMed Web of Science ®Google Scholar
• Perez-Soler R., Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?. J. Clin. Oncol. 2005; 23(22)5235–5246
   PubMed Web of Science ®Google Scholar
• Goodin S. Erlotinib: optimizing therapy with predictors of response?. Clin. Cancer Res. 2006; 12(10)2961–2913
   PubMed Web of Science ®Google Scholar
• Giaccone G., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 1. J. Clin. Oncol. 2004; 22(22)5–777
   Google Scholar
• Herbst R. S., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 2. J. Clin. Oncol. 2004; 22(22)5–785
   Google Scholar
• Amador M. L., et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res. 2004; 64(64)24–9139
   Google Scholar
• Fan Z., et al. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res. 1993; 53(53)19–4637
   PubMedGoogle Scholar
• Robert F., et al. Phase I study of anti–epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J. Clin. Oncol. 2001; 19(13)3234–3243
   PubMed Web of Science ®Google Scholar
• Folprecht G., et al. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann. Oncol. 2006; 17(17)3–450
   PubMedGoogle Scholar
• Cunningham D., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004; 351(351)4–337
   Google Scholar
• Wong S. F. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin. Ther. 2005; 27(6)684–694
   PubMed Web of Science ®Google Scholar
• Marc Peeters E. V.C. Salvatore Siena, Yves Humblet, Alain Hendlisz, Bart Neyns, Jean Luc Canon, Jean Luc Van Laethem, Joan Maurel, Gary Richardson, The Panitumumab Study Team. A phase 3, multicenter, randomized controlled trial (RCT) of panitumumab plus best supportive care (BSC) vs BSC alone in patients (pts) with metastatic colorectal cancer (mCRC). Proceedings of the 97th American Association for Cancer Research Annual Meeting. 2006
   Google Scholar
• FDA News FOR IMMEDIATE RELEASE P06-148 Media Inquiries: Megan Moynahan, 301-827-6242
   Google Scholar
• Moore M. J., et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. 2005, A phase III trial of the National Cancer Institute of Canada Clinical Trial Group [NCIC-CTG]. Abstract #1
   Google Scholar
• Pollack A. MARKET PLACE; Panel Backs One Drug, But Not 2nd. New York Times 2005; 3, New York
   Google Scholar